Background Low-molecular-weight heparin is known to be safeand effective for the initial treatment of patients with proximaldeep-vein thrombosis. However, its application to patients withpulmonary embolism or previous episodes of thromboembolism hasnot been studied.
Methods We randomly assigned 1021 patients with symptomaticvenous thromboembolism to fixed-dose, subcutaneous low-molecular-weightheparin (reviparin sodium) or adjusted-dose, intravenous unfractionatedheparin. Oral anticoagulant therapy with a coumarin derivativewas started concomitantly and continued for 12 weeks. Approximatelyone third of the patients had associated pulmonary embolism.The outcome events studied over the 12 weeks were symptomaticrecurrent venous thromboembolism, major bleeding, and death.We sought to determine whether low-molecular-weight heparinis at least equivalent to unfractionated heparin in patientswith venous thromboembolism.
Results Twenty-seven of the 510 patients assigned to low-molecular-weightheparin (5.3 percent) had recurrent thromboembolic events, ascompared with 25 of the 511 patients assigned to unfractionatedheparin (4.9 percent). The difference of 0.4 percentage pointindicates that the two therapies have equivalent value accordingto our predetermined definition of equivalence. Sixteen patientsassigned to low-molecular-weight heparin (3.1 percent) and 12patients assigned to unfractionated heparin (2.3 percent) hadepisodes of major bleeding (P = 0.63), and the mortality ratesin the two groups were 7.1 percent and 7.6 percent, respectively(P = 0.89).
Conclusions Fixed-dose, subcutaneous low-molecular-weight heparinis as effective and safe as adjusted-dose, intravenous unfractionatedheparin for the initial management of venous thromboembolism,regardless of whether the patient has pulmonary embolism ora history of venous thromboembolism.
In Western countries, each year 2 to 4 persons per 1000 requireanticoagulant therapy for symptomatic deep-vein thrombosis orpulmonary embolism.1,2,3 Although deep-vein thrombosis and pulmonaryembolism were previously regarded as separate clinical entities,there is good evidence that they are expressions of a singledisease process — namely, venous thromboembolism.4,5,6
Until recently, the standard treatment of patients with venousthromboembolism was hospital admission, with unfractionatedheparin given by intravenous infusion for 5 to 10 days, followedby oral anticoagulant therapy for at least 3 months.7,8 Becausepatients vary widely in their anticoagulant response to unfractionatedheparin, frequent laboratory monitoring with appropriate doseadjustment is needed to keep their level of anticoagulationin the therapeutic range. In contrast, the longer half-lifeof low-molecular-weight heparins and the more predictable anticoagulantresponse make them suitable for subcutaneous administrationwithout laboratory monitoring.
Initial trials in hospitalized patients with proximal deep-veinthrombosis showed that low-molecular-weight heparin in a dosedetermined by body weight alone is at least as effective andsafe as unfractionated heparin.9,10 Two further recent trialshave had similar results when low-molecular-weight heparin wasgiven mainly on an outpatient basis to suitable patients withproximal deep-vein thrombosis.11,12 However, using due caution,these studies excluded patients with symptoms of pulmonary embolismand some patients with a history of venous thromboembolism,because such patients are thought to have more serious thromboembolicdisease. Before the widespread use of low-molecular-weight heparinis recommended, the effectiveness of these agents in treatingthe full spectrum of patients with venous thromboembolism mustbe confirmed.
We report the results of a large, open, international, randomizedclinical trial designed to determine whether fixed-dose, subcutaneouslow-molecular-weight heparin and adjusted-dose, continuous intravenousunfractionated heparin have at least equivalent efficacy inunselected patients with symptomatic venous thromboembolism.We studied the clinical outcomes of recurrent venous thromboembolism,hemorrhage, and death during 12 weeks of follow-up, with blindedvalidation of outcome events by a central adjudication committee.
Methods
Study Patients
Consecutive patients with acute, symptomatic deep-vein thrombosis,pulmonary embolism, or both who were considered to require antithrombotictherapy were eligible for the study. The symptomatic deep-veinthrombosis could be limited to the calf or could involve thepopliteal vein or a more proximal vein; the diagnosis had tobe documented by ultrasonography or venography. Clinically suspectedpulmonary embolism was confirmed by ventilation–perfusionlung scanning that showed a high probability of pulmonary embolismor by pulmonary angiography or, if lung scanning was nondiagnostic,by the demonstration of deep-vein thrombosis on compressionultrasonography or venography.5,6
Patients who met these criteria for inclusion were ineligiblefor the study if they had received therapeutic doses of low-molecular-weightheparin, unfractionated heparin, or oral anticoagulant therapyfor more than 24 hours; if anticoagulant therapy was contraindicated;if thrombolytic therapy was planned; if they had had gastrointestinalbleeding in the preceding 14 days; if they had undergone surgeryrequiring anesthesia within the previous 3 days; if they hadhad a stroke in the preceding 10 days; if the platelet countwas less than 100,000 per cubic millimeter; if they weighedless than 35 kg; if they were less than 18 years old; if theyhad a documented pregnancy or had childbearing potential butwere not using adequate contraception; or if they were in alocation that made follow-up difficult. Patients were enrolledwhether venous thromboembolism developed in the hospital orwhile the patients were outpatients. The feasibility of treatmentat home was not considered in assessing eligibility. After thepatient gave informed consent, randomization (stratified accordingto whether the patient presented with deep-vein thrombosis onlyor with pulmonary embolism, and also stratified according toclinical center) was performed with a computer algorithm andthe use of a central 24-hour telephone service that recordedinformation on the patient before the treatment assignment wasdisclosed. The study protocol was approved by the institutionalreview boards of all the clinical centers.
Treatment Regimens
The patients randomly assigned to low-molecular-weight heparinreceived reviparin sodium (Clivarin, Knoll, Ludwigshafen, Germany),administered subcutaneously in the following fixed doses: 6300anti–factor Xa units twice daily (according to the firstinternational standard for low-molecular-weight heparin), forpatients weighing more than 60 kg; 4200 units twice daily, forpatients weighing 46 to 60 kg; and 3500 units twice daily, forpatients weighing 35 to 45 kg. Patients could be treated athome, but the decision to do so was left to the treating physician.Patients who received some or all of their treatment at homewere instructed by a nurse in the method of self-injection.When self-administration was not feasible, the injections weregiven by a relative or a nurse.
The patients randomly assigned to unfractionated heparin weretreated in the hospital. They received an intravenous bolusinjection of 5000 IU (Liquemin, Roche, Basel, Switzerland),followed by a dose of 1250 IU per hour given by continuous intravenousinfusion and adjusted according to a nomogram.13 In practice,the clinical centers used an activated partial-thromboplastintime of 60 to 85 seconds as a target value or a fixed ratioof 1.5 to 2.5 times a control value.8 These tests were performed6 to 12 hours after the start of treatment or 6 to 12 hoursafter a subtherapeutic activated partial-thromboplastin timewas measured, and otherwise daily.
Oral anticoagulant treatment with a derivative of coumarin wasbegun on the first or second day and continued for a total of12 weeks. During treatment with the study drug, prothrombintimes were measured at least every other day, with the doseadjusted to achieve an international normalized ratio of 2.0to 3.0. The study drug was discontinued when the internationalnormalized ratio was maintained above 2.0 for two consecutivedays and the patient had received the study drug for at leastfive days.
Surveillance and Follow-Up
All the patients were contacted daily during the initial treatment,after 14 days, and after 12 weeks. At each visit, a checklistwas used to elicit information on symptoms and signs of recurrentvenous thromboembolism and bleeding. All the patients were instructedto report to the clinical center on an emergency basis if anynew symptoms developed that were suggestive of deep-vein thrombosisor pulmonary embolism. In cases of suspected deep-vein thrombosis(for example, when there was increased pain or swelling in theleg) or pulmonary embolism (for example, when there was dyspneaor chest pain), the patients underwent appropriate diagnostictests. The investigators were asked to report all clinicallyunusual episodes of bleeding.
During the initial treatment, platelet counts were obtainedevery third day. Hemoglobin and the hematocrit were measured,and platelet counts obtained, at base line and after 14 days.
Assessment of Clinical Outcomes
The principal outcome events were objectively confirmed symptomaticdeep-vein thrombosis or pulmonary embolism and major bleedingwithin 12 weeks of randomization. Information on all suspectedoutcome events and deaths was reviewed and classified by a centraladjudication committee whose members were unaware of the treatmentassignments. A training session was held at the start of thestudy concerning the techniques and interpretation of the diagnostictests used.
The criteria for the diagnosis of symptomatic deep-vein thrombosiswere as follows: an extension of an intraluminal filling defecton a venogram; a new intraluminal filling defect or an extensionof the nonvisualization of proximal veins in the presence ofa sudden cutoff defect on a venogram that was seen on at leasttwo projections; if no previous venogram was available for comparison,an intraluminal filling defect; if no venogram was available,abnormal results of compression ultrasonography in an area wherecompression had been normal or a substantial increase in thediameter of the thrombus during full compression at the poplitealor femoral vein11,12; or, if neither a venogram nor an ultrasonographicstudy was available, a change in the results of impedance plethysmographyfrom normal to abnormal. The criteria for the diagnosis of symptomaticpulmonary embolism were as follows: a new intraluminal fillingdefect, an extension of an existing defect, or the sudden cutoffof vessels more than 2.5 mm in diameter on a pulmonary angiogram;if no prior angiogram was available, an intraluminal fillingdefect or a sudden cutoff of vessels more than 2.5 mm in diameteron a pulmonary angiogram; or if no pulmonary angiogram was available,a defect of at least 75 percent of a segment on the perfusionscan, with normal ventilation. If the ventilation–perfusionscan was nondiagnostic (and no pulmonary angiogram was available),satisfaction of the criteria for deep-vein thrombosis was acceptable;or pulmonary embolism could be demonstrated at autopsy. Onlyif no adequate objective tests had been performed did the adjudicationcommittee base its final decision on the clinical informationprovided.
Bleeding was defined as major if it was clinically overt andassociated with a fall in the hemoglobin level of at least 2.0g per deciliter or a need for the transfusion of 2 or more unitsof red cells; if it was retroperitoneal or intracranial; orif it warranted the permanent discontinuation of treatment.Deaths were classified as due to pulmonary embolism (when therewas substantive evidence), sudden death, hemorrhage, or anothercause.
Statistical Analysis
On the basis of two recent studies comparing low-molecular-weightheparin with unfractionated heparin, we assumed a 7 percentincidence of recurrent venous thromboembolism with unfractionatedheparin and a 20 percent reduction in the relative risk of recurrentvenous thromboembolism associated with the use of low-molecular-weightheparin.11,12 On the basis of the previously observed absoluterisk reduction of 12 percentage points associated with the useof unfractionated heparin as compared with placebo,14 we tookan increase of 3 percentage points as the threshold value indicatingclinical equivalence. From these assumptions, a study of 1000patients would provide an 80 percent probability (power) ofrejecting, with a one-sided test at a significance level of0.05, the hypothesis that the rate of recurrence with low-molecular-weightheparin would be more than 3 percentage points higher than thatwith unfractionated heparin in the entire group of patientswith venous thromboembolism.
The rates of recurrent venous thromboembolism were comparedby the method of Blackwelder.15 This statistical test evaluateswhether the observed difference excludes the specified thresholdfor equivalence. For the comparisons of subgroups, the chi-squaretest (two-sided) was used.
Results
Study Patients
The recruitment of patients began in November 1994 and endedin October 1995. The follow-up of the patients was completedin February 1996. A total of 1745 consecutive patients met theeligibility criteria, among whom 424 (24 percent) met one ormore of the criteria for exclusion. The three most common reasonsfor the exclusion of patients were the use of therapeutic dosesof low-molecular-weight heparin, unfractionated heparin, ororal anticoagulant therapy for more than 24 hours (200 patients);contraindications to anticoagulant therapy (68 patients); anddifficulty with follow-up because of geographic location (59patients). Only 12 patients with pulmonary embolism were excludedfrom the study because thrombolytic therapy was planned. Ofthe 1321 eligible patients, 1021 (77 percent) gave informedconsent and were randomly assigned to low-molecular-weight heparin(510 patients) or unfractionated heparin (511). The base-linecharacteristics of the patients in the two treatment groupswere similar, as Table 1 shows.
Table 1. Base-Line Characteristics of the Study Patients.
Treatment and Follow-Up
Data on the initial treatment, hospitalization, and oral anticoagulationare shown in Table 2. The initial heparin treatment lasted approximatelysix days in both treatment groups, and the international normalizedratio was in the therapeutic range for similar proportions oftime in the two groups. The mean hospital stay was three daysless in the group assigned to low-molecular-weight heparin,mainly because 100 of the 372 patients with deep-vein thrombosisassigned to that group (27 percent) were not admitted to thehospital for treatment of their deep-vein thrombosis. Another56 of the patients with deep-vein thrombosis in that group (15percent) were discharged during the first three days of treatment.Compliance with treatment and with the study protocol was high,and no patient was lost to follow-up.
Table 2. Data on the Initial Heparin Treatment, Hospitalization, and Oral Anticoagulant Therapy.
Recurrent Venous Thromboembolism
Among the 510 patients treated with low-molecular-weight heparin,82 patients had a total of 98 episodes of clinically suspectedrecurrent venous thromboembolism. Of these episodes, 29 (in27 patients, or 5.3 percent of the total) met the criteria fordocumented recurrent venous thromboembolism. Among the 511 patientstreated with unfractionated heparin, 75 had a total of 88 suspectedepisodes that were adjudicated, and 30 episodes (in 25 patients,or 4.9 percent) met the criteria. The absolute difference of0.4 percentage point between these rates indicates equivalencebetween the treatments, since it rules out an increase of 2.7percentage points or more with low-molecular-weight heparinas compared with standard heparin at the 95 percent level ofconfidence (P = 0.030 for the comparison with the preset differenceof 3 percentage points).
The majority of the recurrent venous thromboembolic events occurredduring the first 14 days, and the risk of recurrence decreasedover time (Table 3). In 17 of the 27 patients assigned to low-molecular-weightheparin who had recurrences, the event was symptomatic deep-veinthrombosis; in the unfractionated-heparin group, the correspondingnumber was 13 of 25. In all patients except one, recurrent episodesof venous thromboembolism were documented by objective testsor at autopsy. Adjustment by logistic-regression analysis fordifferences in age and in the frequency of recent surgery atbase line did not alter the results of the study.
Table 3. Rates of Recurrent Venous Thromboembolism, Major Bleeding, and Death during the Study.
Bleeding Complications
Among the reported instances of clinically important bleeding,93 were confirmed by the central adjudication committee, and28 of them met the criteria for major bleeding. There were 46events among the patients treated with low-molecular-weightheparin and 47 among those treated with unfractionated heparin;16 and 12 of these, respectively, involved major bleeding. AsTable 3 shows, the majority of instances of bleeding occurredduring the first 14 days of the study.
Mortality
During the 12 weeks of follow-up, 75 patients (7.3 percent)died: 36 who were treated with low-molecular-weight heparin(7.1 percent) and 39 who were treated with unfractionated heparin(7.6 percent). The mortality rate remained fairly constant overtime (Table 3). Among the 36 deaths of patients treated withlow-molecular-weight heparin, 3 (on days 3, 4, and 35) wereclassified as due to pulmonary embolism and 3 (on days 18, 55,and 73) were considered sudden. There were no instances of fatalbleeding in this group. Among the 39 deaths in the unfractionated-heparingroup, there were 3 fatal episodes of pulmonary embolism (ondays 3, 24, and 64), 2 sudden deaths (on days 19 and 44), and2 instances of fatal bleeding (on days 4 and 5). All six fatalepisodes of pulmonary embolism occurred in patients who hadpulmonary embolism at presentation.
Additional Observations
Among the 271 patients with pulmonary embolism at presentation,16 had symptomatic recurrent venous thromboembolism (5.9 percent;8 patients in each treatment group), as compared with 36 ofthe 750 patients presenting with deep-vein thrombosis only (4.8percent; 19 patients treated with low-molecular-weight heparinand 17 treated with unfractionated heparin). Among the 16 patientspresenting with pulmonary embolism who had recurrent thromboembolism,11 (69 percent) had recurrences of pulmonary embolism, whereaspulmonary embolism occurred in only 11 of the 36 patients withdeep-vein thrombosis at presentation (31 percent, P = 0.023).Among the 232 patients with cancer at base line, 20 (8.6 percent)had symptomatic recurrent venous thromboembolism, as comparedwith only 32 (4.1 percent) of the remaining 789 patients (P= 0.009). Forty-seven of the patients with cancer (20.3 percent)died, as compared with 28 (3.5 percent) of those without cancer(P<0.001).
The relative effects of low-molecular-weight heparin and unfractionatedheparin with respect to the three major clinical outcomes weresimilar in all these subgroups. They were also similar in othersubgroups, such as patients with a history of venous thromboembolismand patients without such a history.
Discussion
Previous randomized trials have shown that subcutaneous, low-molecular-weightheparin is likely to be at least as effective and safe as unfractionatedheparin in treating patients with uncomplicated deep-vein thrombosis.16,17,18However, because these trials did not include patients withpulmonary embolism and because some patients with a historyof venous thromboembolism were excluded, clinicians may legitimatelybe concerned that the findings may not translate directly totheir own clinical practice.19
We studied a broad range of patients, including a large subgroupwith pulmonary embolism, in many hospitals in several countries.Unmonitored, subcutaneous low-molecular-weight heparin was shownto be an effective and safe treatment for patients with venousthromboembolism. We observed similar treatment effects in eachof various sizable subgroups — patients with pulmonaryembolism, cancer, or previous thromboembolism and those withouteach of these conditions. We also included patients with symptomaticcalf-vein thrombosis, who would normally receive anticoagulanttherapy, since it has been documented that such patients areat risk for recurrent venous thromboembolism if left untreated.20Our predetermined criterion for equivalence between the treatmentswas an absolute increase in the recurrence rate of no more than3 percentage points with low-molecular-weight heparin. Sinceour findings showed that there was no such difference, one mayconclude that the treatments are equivalent for patients withvenous thromboembolism. It should be understood that the studydid not have the power to detect differences among subgroupsof patients.
Thus, in terms of safety and efficacy, low-molecular-weightheparin offers an appropriate alternative to unfractionatedheparin in patients with venous thromboembolism. In addition,low-molecular-weight heparin has several practical advantages.Since there is no need for laboratory monitoring or infusion,suitable patients can be treated at home, either throughouttheir care or after early discharge from the hospital.11,12Those requiring hospital admission also benefit because theyavoid the inconvenience and hazards of intravenous lines.
Because this was an open trial, care was taken to minimize thepotential for bias. We included consecutive patients, used centralrandomization by telephone, and ensured that follow-up was completefor all randomized patients. Furthermore, all clinically suspectedoutcome events were assessed by an independent, blinded centraladjudication committee on the basis of predetermined criteria.
Meta-analyses of early trials of low-molecular-weight heparinsfor the treatment of deep-vein thrombosis have suggested that,as compared with unfractionated heparin, these agents may beassociated with reductions as large as 50 percent in the relativerisk of recurrent thrombosis.16,17,18 Our findings are inconsistentwith a reduction of this magnitude. Explanations for the apparentdiscrepancy, other than that it occurred by chance, includethe possibility that low-molecular-weight heparins are associatedwith a more modest reduction, if any. This possibility is supportedby two recent studies.11,12 It is noteworthy that the ratesof recurrent venous thromboembolism with low-molecular-weightheparins in the various treatment trials are consistent, around4 to 5 percent, whereas the rates among the groups treated withunfractionated heparin vary more widely; the latter variationmay be due in part to differences in the regimens of unfractionatedheparin in the different trials.9,10,11,12,21,22,23,24 The incidenceof major bleeding reported for both groups in this study isconsistent with that reported previously.16,17,18
Overall, the rates of recurrence we observed were low, whetherpatients were treated with low-molecular-weight heparin or withunfractionated heparin. In patients with cancer, however, therecurrence rate was doubled in both treatment groups, suggestingthat anticoagulant therapy in these patients needs further improvement.
We conclude that low-molecular-weight heparin and unfractionatedheparin are equally effective and safe in unselected patientswith confirmed deep-vein thrombosis, with or without associatedpulmonary embolism. In addition, low-molecular-weight heparinpermits treatment regimens to be simplified so that hospitalstays can be shortened and suitable patients can be treatedoutside the hospital.
Supported by a grant from Knoll AG, Ludwigshafen, Germany.
* The institutions and investigators participating in the studyare listed in the Appendix.
Source Information
The Writing Committee of the Columbus Study (H.R. Büller, M. Gent, A.S. Gallus, J. Ginsberg, M.H. Prins, and R. Baildon) takes responsibility for the content of this article.
Address reprint requests to Professor J.W. ten Cate, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam Zuid-oost, the Netherlands.
References
Kierkegaard A. Incidence of acute deep vein thrombosis in two districts: a phlebographic study. Acta Chir Scand 1980;146:267-269. [Medline]
Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-160. [Medline]
van Beek EJR, Büller HR, ten Cate JW. Epidemiology of venous thromboembolism. In: Tooke JE, Lowe GD, eds. A textbook of vascular medicine. London: Arnold, 1996:471-88.
Huisman MV, Büller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989;95:498-502. [Free Full Text]
Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983;98:891-899.
Kruit WHJ, de Boer AC, Sing AK, van Roon F. The significance of venography in the management of patients with clinically suspected pulmonary embolism. J Intern Med 1991;230:333-339. [Medline]
Clark S. Current issues in management of thrombosis. Lancet 1995;346:113-114. [Medline]
Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574. [Medline]
Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445. [CrossRef][Medline]
Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982. [Abstract]
Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681. [Free Full Text]
Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687. [Free Full Text]
Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-337. [Free Full Text]
Brandjes DPM, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-1489. [Abstract]
Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials 1982;3:345-353. [CrossRef][Medline]
Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995;155:601-607. [Free Full Text]
Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-277. [CrossRef][Medline]
Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309:299-304. [Free Full Text]
Schafer AI. Low-molecular-weight heparin -- an opportunity for home treatment of venous thrombosis. N Engl J Med 1996;334:724-725. [Free Full Text]
Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-518. [Medline]
Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992;68:14-18. [Medline]
Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-1546. [Free Full Text]
Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-190. [Medline]
Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): results of a double-blind randomized study. Circulation 1989;80:935-940. [Free Full Text]
Appendix
In addition to the members of the Writing Committee, the followinginstitutions and investigators participated in the study. ExecutiveCommittee: J.W. ten Cate, H.R. Büller, M. Gent, J. Hirsh,M.H. Prins, and R. Baildon; Adjudication Committee: A.W.A. Lensing,D.R. Anderson, and E.J.R. van Beek; Safety Committee: J.N. Fiesingerand J.G.P. Tijssen; Coordination and Data Management Centers:Academic Medical Center, University of Amsterdam, Amsterdam— A. van Barneveld, L.T. Eimers, Y.P. Graafsma, R. Hettiarachchi,B. Hutten, and K. Redekop; Hamilton Civic Hospitals ResearchCenter, Hamilton, Ont., Canada — S. Haley, L. Liberale,T. Finch, S. Whittaker, and L. Wilkinson; Participating Centers(the number of patients contributed by the center follows thename of the center): Institute of Medical Semiotics, Padua,Italy (96) — P. Prandoni, S. Villalta, B. Girolami, P.Bagatella, L. Rossi, and A. Girolami; Medicina Interna e OncologiaMedica, Policlinico "San Matteo," Pavia, Italy (81) —F. Piovella, M. Barone, C. Beltrametti, S. Serafini, S. Siragusa,and E. Ascari; Victoria Hospital and University of Western Ontario,London, Ont., Canada (75) — M.J. Kovacs, B. Morrow, andJ. Kovacs; Academic Medical Center, University of Amsterdam,Amsterdam (71) — P.M.M. Kuijer, M.M.W. Koopman, and H.Jagt; Hamilton Civic Hospitals, Henderson General Division,Hamilton, Ont., Canada (53) — J. Weitz, C. Kearon, andL. Biagioni; Krankenhaus Bogenhaussen–Medizinische Poliklinik,Munich, Germany (52) — S. Haas, F. Lössner, F.A.Spengel, and M. Berger; Hôpital du Saint-Sacrement, Quebec,Que., Canada (51) — C. Demers and J. Poulin; UniversityHospital Groningen, Groningen, the Netherlands (41) —J. van der Meer, G.T.H. Que, and W.M. Smid; Victoria GeneralHospital, Halifax, N.S., Canada (38) — D.R. Anderson,K.S. Robinson, and E. Boyle; Montreal General Hospital, Montreal(35) — J.R. Leclerc, B. St. Jacques, and S. Finkenbine;Flinders Medical Centre, Adelaide, Australia (33) — A.S.Gallus, D. Cohlan, and C. Rich; Slotervaart Hospital, Amsterdam(33) — D.P.M. Brandjes, C.A. Hoefnagel, M. de Rijk, andF. Turkstra; Centre Hospitalier de l'Université Laval,Quebec, Que., Canada (30) — L. Desjardins, J. Cote-Desjardins,L. Couture, M. Ruel, and J. Villeneuve; Sunnybrook Health ScienceCentre, Toronto (29) — W.H. Geerts, R.M. Jay, and K.I.Code; Hamilton Civic Hospitals, Hamilton General Division, Hamilton,Ont., Canada (29) — A.G.G. Turpie and J. Johnson; HôtelDieu, Montreal (28) — P. Nguyen, J.R. Cusson, and S. Roy;Ottawa Civic Hospital, Ottawa, Ont., Canada (28) — P.S.Wells, J. Bormanis, and D. Goudie; University Hospital, London,Ont., Canada (26) — M. Cruickshank and M. von Lewinski;Hospital Germans Trias i Pujol, Barcelona, Spain (24) —M. Monreal, J.C. Sahuquillo, and E. Lafoz; Hôpital AntoineBéclère, Clamart, France (20) — G. Simonneau,F. Parent, and J. Jagot; St. Joseph's Hospital, Hamilton, Ont.,Canada (19) — J.D. Douketis and K. Kinnon; McMaster UniversityMedical Centre, Hamilton, Ont., Canada (19) — J.S. Ginsberg,P. Brill-Edwards, and D. Donovan; Auckland Hospital, Auckland,New Zealand (18) — P.A. Ockelford; Hôpital Maisonneuve-Rosemount,Montreal (18) — J. Kassis and S. Bornais; Centre HospitalierUniversitaire Hôtel Dieu, Nantes, France (17) —B. Planchon, D. El Kouri, and M.A. Pistorius; Hospital de 12Octubre, Madrid (13) — M. Escribano and G. Garrido; Princeof Wales Hospital, Sydney, Australia (13) — C.N. Chesterman,B.H. Chong, and S. Pritchard; Royal Melbourne Hospital, Melbourne,Australia (10) — J.F. Cade, T. Bynon, and J. Stanford;St. Joseph's Health Centre, London, Ont., Canada (9) —W.M. Brien and B. Palmer; Clinique Saint Vincent, Besançon,France (9) — R. Faivre and P.Y. Petiteau; Hemophilia andThrombosis Center A. Bianchi Bonomi, Maggiore Hospital, Milan,Italy (5) — P.M. Manucci, M. Moia, and P. Bucciarelli.
Lee, A. Y.Y.
(2009). Anticoagulation in the Treatment of Established Venous Thromboembolism in Patients With Cancer. JCO
27: 4895-4901
[Abstract][Full Text]
Soto-Cardenas, M., Pelayo-Garcia, G, Rodriguez-Camacho, A, Segura-Fernandez, E, Mogollo-Galvan, A, Giron-Gonzalez, J.
(2008). Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med
22: 965-968
[Abstract]
Rodger, M. A. MD MSc, Kahn, S. R. MD MSc, Wells, P. S. MD MSc, Anderson, D. A. MD, Chagnon, I. MD, Le Gal, G. MD PhD, Solymoss, S. MD, Crowther, M. MD, Perrier, A. MD, White, R. MD, Vickars, L. MD, Ramsay, T. PhD MSc, Betancourt, M. T. MD MSc, Kovacs, M. J. MD
(2008). Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ
179: 417-426
[Abstract][Full Text]
Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N.
(2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 257S-298S
[Abstract][Full Text]
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., Comerota, A. J.
(2008). Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 454S-545S
[Abstract][Full Text]
Laporte, S., Mismetti, P., Decousus, H., Uresandi, F., Otero, R., Lobo, J. L., Monreal, M., the RIETE Investigators,
(2008). Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous Thromboembolism: Findings From the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation
117: 1711-1716
[Abstract][Full Text]
Tapson, V. F.
(2008). Acute Pulmonary Embolism. NEJM
358: 1037-1052
[Full Text]
Janjigian, M. P., Muhs, B. E.
(2008). Current Treatment of Acute Lower Extremity Deep Venous Thrombosis. INT J LOW EXTREM WOUNDS
7: 15-20
[Abstract]
Spencer, F. A., Gore, J. M., Lessard, D., Douketis, J. D., Emery, C., Goldberg, R. J.
(2008). Patient Outcomes After Deep Vein Thrombosis and Pulmonary Embolism: The Worcester Venous Thromboembolism Study. Arch Intern Med
168: 425-430
[Abstract][Full Text]
Spyropoulos, A. C.
(2008). Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin. CLIN APPL THROMB HEMOST
14: 63-74
[Abstract]
Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F.S., May, H. T., Samuelson, K. M., Muhlestein, J. B., Carlquist, J. F., for the Couma-Gen Investigators,
(2007). Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. Circulation
116: 2563-2570
[Abstract][Full Text]
Tapson, V. F., Huisman, M. V.
(2007). Home at last? Early discharge for acute pulmonary embolism. Eur Respir J
30: 613-615
[Full Text]
Davies, C. W. H., Wimperis, J., Green, E. S., Pendry, K., Killen, J., Mehdi, I., Tiplady, C., Kesteven, P., Rose, P., Oldfield, W.
(2007). Early discharge of patients with pulmonary embolism: a two-phase observational study. Eur Respir J
30: 708-714
[Abstract][Full Text]
The van Gogh Investigators,
(2007). Idraparinux versus Standard Therapy for Venous Thromboembolic Disease. NEJM
357: 1094-1104
[Abstract][Full Text]
Nishioka, J., Goodin, S.
(2007). Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. J Oncol Pharm Pract
13: 85-97
[Abstract]
Rimola, J., Perendreu, J., Falco, J., Fortuno, J. R., Massuet, A., Branera, J.
(2007). Percutaneous Arterial Embolization in the Management of Rectus Sheath Hematoma. Am. J. Roentgenol.
188: W497-W502
[Abstract][Full Text]
Nijkeuter, M., Sohne, M., Tick, L. W., Kamphuisen, P. W., Kramer, M. H. H., Laterveer, L., van Houten, A. A., Kruip, M. J. H. A., Leebeek, F. W. G., Buller, H. R., Huisman, M. V.
(2007). The Natural Course of Hemodynamically Stable Pulmonary Embolism: Clinical Outcome and Risk Factors in a Large Prospective Cohort Study. Chest
131: 517-523
[Abstract][Full Text]
Nutescu, E. A, Wittkowsky, A. K, Dobesh, P. P, Hawkins, D. W, Dager, W. E
(2006). Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach. The Annals of Pharmacotherapy
40: 1558-1570
[Abstract][Full Text]
Kearon, C., Ginsberg, J. S., Julian, J. A., Douketis, J., Solymoss, S., Ockelford, P., Jackson, S., Turpie, A. G., MacKinnon, B., Hirsh, J., Gent, M., for the Fixed-Dose Heparin (FIDO) Investigators,
(2006). Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.. JAMA
296: 935-942
[Abstract][Full Text]
Piazza, G., Goldhaber, S. Z.
(2006). Acute Pulmonary Embolism: Part II: Treatment and Prophylaxis. Circulation
114: e42-e47
[Full Text]
Sheehan, J. P., Walke, E. N.
(2006). Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism. Blood
107: 3876-3882
[Abstract][Full Text]
Ellis, M. H., Hadari, R., Tchuvrero, N., Shapira, S., Kovlenko, I., Kozmiakova, M., Zissin, R., Elis, A.
(2006). Hemorrhagic Complications in Patients Treated with Anticoagulant Doses of a Low Molecular Weight Heparin (Enoxaparin) in Routine Hospital Practice. CLIN APPL THROMB HEMOST
12: 199-204
[Abstract]
Rodger, M. A., Bredeson, C. N., Jones, G., Rasuli, P., Raymond, F., Clement, A. M., Karovitch, A., Brunette, H., Makropoulos, D., Reardon, M., Stiell, I., Nair, R., Wells, P. S.
(2006). The Bedside Investigation of Pulmonary Embolism Diagnosis Study: A Double-blind Randomized Controlled Trial Comparing Combinations of 3 Bedside Tests vs Ventilation-Perfusion Scan for the Initial Investigation of Suspected Pulmonary Embolism. Arch Intern Med
166: 181-187
[Abstract][Full Text]
Prandoni, P.
(2005). How I treat venous thromboembolism in patients with cancer. Blood
106: 4027-4033
[Abstract][Full Text]
Rashid, S T, Thursz, M R, Razvi, N A, Voller, R, Orchard, T, Rashid, S T, Shlebak, A A
(2005). Venous thromboprophylaxis in UK medical inpatients. JRSM
98: 507-512
[Abstract][Full Text]
Kucher, N., Quiroz, R., McKean, S., Sasahara, A. A, Goldhaber, S. Z
(2005). Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vasc Med
10: 251-256
[Abstract]
Harris, T, Meek, S
(2005). When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature. Emerg. Med. J.
22: 766-771
[Abstract][Full Text]
Mismetti, P., Quenet, S., Levine, M., Merli, G., Decousus, H., Derobert, E., Laporte, S.
(2005). Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism: An Individual Patient Data Meta-analysis. Chest
128: 2203-2210
[Abstract][Full Text]
Dager, W. E, King, J. H, Branch, J. M, Chow, S. L, Ferrer, R. E, Pak, S., Togioka, P. Y, White, R. H
(2005). Tinzaparin in Outpatients with Pulmonary Embolism or Deep Vein Thrombosis. The Annals of Pharmacotherapy
39: 1182-1187
[Abstract][Full Text]
Wells, P. S., Anderson, D. R., Rodger, M. A., Forgie, M. A., Florack, P., Touchie, D., Morrow, B., Gray, L., O'Rourke, K., Wells, G., Kovacs, J., Kovacs, M. J.
(2005). A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Arch Intern Med
165: 733-738
[Abstract][Full Text]
Fiessinger, J.-N., Huisman, M. V., Davidson, B. L., Bounameaux, H., Francis, C. W., Eriksson, H., Lundstrom, T., Berkowitz, S. D., Nystrom, P., Thorsen, M., Ginsberg, J. S., for the THRIVE Treatment Study Investigators,
(2005). Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis: A Randomized Trial. JAMA
293: 681-689
[Abstract][Full Text]
Syed, F.F., Beeching, N.J.
(2005). Lower-limb deep-vein thrombosis in a general hospital: risk factors, outcomes and the contribution of intravenous drug use. QJM
98: 139-145
[Abstract][Full Text]
Pineo, G. F., Hull, R. D.
(2005). Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly. CLIN APPL THROMB HEMOST
11: 15-23
[Abstract]
Kovacs, M.J., Kearon, C., Rodger, M., Anderson, D.R., Turpie, A.G.G., Bates, S.M., Desjardins, L., Douketis, J., Kahn, S.R., Solymoss, S., Wells, P.S.
(2004). Single-Arm Study of Bridging Therapy With Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin. Circulation
110: 1658-1663
[Abstract][Full Text]
Karne, A., Shah, N. R.
(2004). Low-Molecular-Weight Heparin for Pulmonary Embolism. ANN INTERN MED
141: 407-407
[Full Text]
Hirsh, J., Raschke, R.
(2004). Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 188S-203S
[Abstract][Full Text]
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S.
(2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 287S-310S
[Abstract][Full Text]
Buller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., Raskob, G. E.
(2004). Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 401S-428S
[Abstract][Full Text]
Elting, L. S., Escalante, C. P., Cooksley, C., Avritscher, E. B. C., Kurtin, D., Hamblin, L., Khosla, S. G., Rivera, E.
(2004). Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer. Arch Intern Med
164: 1653-1661
[Abstract][Full Text]
Aujesky, D. A., Cornuz, J., Bosson, J.-L., Bounameaux, H., Emmerich, J., Hull, R. D., Mackay, E., Perrier, A., Quan, H., Tsuyuki, R. T., Ghali, W. A.
(2004). Uptake of new treatment strategies for deep vein thrombosis: an international audit. Int J Qual Health Care
16: 193-200
[Abstract][Full Text]
Buller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., Segers, A. E.M., Cariou, R., Leeuwenkamp, O., Lensing, A. W.A., The Matisse Investigators*,
(2004). Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis: A Randomized Trial. ANN INTERN MED
140: 867-873
[Abstract][Full Text]
Pengo, V., Lensing, A. W.A., Prins, M. H., Marchiori, A., Davidson, B. L., Tiozzo, F., Albanese, P., Biasiolo, A., Pegoraro, C., Iliceto, S., Prandoni, P., the Thromboembolic Pulmonary Hypertension Study Gr,
(2004). Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism. NEJM
350: 2257-2264
[Abstract][Full Text]
Writing Committee for the Galilei Investigators,
(2004). Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparin in the Initial Treatment of Venous Thromboembolism. Arch Intern Med
164: 1077-1083
[Abstract][Full Text]
Quinlan, D. J., McQuillan, A., Eikelboom, J. W.
(2004). Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials. ANN INTERN MED
140: 175-183
[Abstract][Full Text]
Deitcher, S. R.
(2004). Undue Extension of Hospital Stay Associated With Anticoagulation. Mayo Clin Proc.
79: 157-158
Eichinger, S., Weltermann, A., Minar, E., Stain, M., Schonauer, V., Schneider, B., Kyrle, P. A.
(2004). Symptomatic Pulmonary Embolism and the Risk of Recurrent Venous Thromboembolism. Arch Intern Med
164: 92-96
[Abstract][Full Text]
Baldwin, Z. K., Comerota, A. J., Schwartz, L. B.
(2004). Catheter-Directed Thrombolysis for Deep Venous Thrombosis. VASC ENDOVASCULAR SURG
38: 1-9
[Abstract]
Linkins, L.-A., Choi, P. T., Douketis, J. D.
(2003). Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis. ANN INTERN MED
139: 893-900
[Abstract][Full Text]
The Matisse Investigators,
(2003). Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism. NEJM
349: 1695-1702
[Abstract][Full Text]
Lee, A. Y.Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., Gent, M., the Randomized Comparison of Low-Molecular-Weight,
(2003). Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. NEJM
349: 146-153
[Abstract][Full Text]
van Dongen, C. J. J., Vink, R., Hutten, B. A., Buller, H. R., Prins, M. H.
(2003). The Incidence of Recurrent Venous Thromboembolism After Treatment With Vitamin K Antagonists in Relation to Time Since First Event: A Meta-analysis. Arch Intern Med
163: 1285-1293
[Abstract][Full Text]
Tovey, C., Wyatt, S.
(2003). Diagnosis, investigation, and management of deep vein thrombosis. BMJ
326: 1180-1184
[Full Text]
Kucher, N., Printzen, G., Goldhaber, S. Z.
(2003). Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism. Circulation
107: 2545-2547
[Abstract][Full Text]
Kovacs, M. J., Rodger, M., Anderson, D. R., Morrow, B., Kells, G., Kovacs, J., Boyle, E., Wells, P. S.
(2003). Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism: A Randomized, Double-Blind, Controlled Trial. ANN INTERN MED
138: 714-719
[Abstract][Full Text]
Raschke, R., Hirsh, J., Guidry, J. R.
(2003). Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin. ANN INTERN MED
138: 720-723
[Abstract][Full Text]
Hylek, E. M., Regan, S., Henault, L. E., Gardner, M., Chan, A. T., Singer, D. E., Barry, M. J.
(2003). Challenges to the Effective Use of Unfractionated Heparin in the Hospitalized Management of Acute Thrombosis. Arch Intern Med
163: 621-627
[Abstract][Full Text]
Masci, G., Magagnoli, M., Zucali, P. A., Castagna, L., Carnaghi, C., Sarina, B., Pedicini, V., Fallini, M., Santoro, A.
(2003). Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?. JCO
21: 736-739
[Abstract][Full Text]
Schafer, A. I., Levine, M. N., Konkle, B. A., Kearon, C.
(2003). Thrombotic Disorders: Diagnosis and Treatment. ASH Education Book
2003: 520-539
[Abstract][Full Text]
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., Girolami, A.
(2002). Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood
100: 3484-3488
[Abstract][Full Text]
Dalen, J. E.
(2002). Pulmonary Embolism: What Have We Learned Since Virchow?: Treatment and Prevention. Chest
122: 1801-1817
[Full Text]
Meyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., Farge, D.
(2002). Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer: A Randomized Controlled Study. Arch Intern Med
162: 1729-1735
[Abstract][Full Text]
Cundiff, D. K.
(2002). Significant Omission in Antithrombotic Supplement. Chest
121: 1378-1379
[Full Text]
Kakkar, V. V., Hoppenstead, D. A., Fareed, J., Kadziola, Z., Scully, M., Nakov, R., Breddin, H. K.
(2002). Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood
99: 1965-1970
[Abstract][Full Text]
Wood, K. E.
(2002). Major Pulmonary Embolism : Review of a Pathophysiologic Approach to the Golden Hour of Hemodynamically Significant Pulmonary Embolism. Chest
121: 877-905
[Abstract][Full Text]
Tait, R C
(2001). Anticoagulation in patients with thromboembolic disease. Thorax
56: ii30-37
[Full Text]
Garg, K., Mao, J.
(2001). Deep Venous Thrombosis: Spectrum of Findings and Pitfalls in Interpretation on CT Venography. Am. J. Roentgenol.
177: 319-323
[Full Text]
Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V.
(2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Arterioscler. Thromb. Vasc. Bio.
21
: e9-e9
[Full Text]
Hamel, E., Pacouret, G., Vincentelli, D., Forissier, J. F., Peycher, P., Pottier, J. M., Charbonnier, B.
(2001). Thrombolysis or Heparin Therapy in Massive Pulmonary Embolism With Right Ventricular Dilation : Results From a 128-Patient Monocenter Registry. Chest
120: 120-125
[Abstract][Full Text]
Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V.
(2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Circulation
103: 2994-3018
[Full Text]
Paterson, D. I., Schwartzman, K.
(2001). Strategies Incorporating Spiral CT for the Diagnosis of Acute Pulmonary Embolism : A Cost-effectiveness Analysis. Chest
119: 1791-1800
[Abstract][Full Text]
Garg, K., Kemp, J. L., Russ, P. D., Baron, A. E.
(2001). Thromboembolic Disease: Variability of Interobserver Agreement in the Interpretation of CT Venography with CT Pulmonary Angiography. Am. J. Roentgenol.
176: 1043-1047
[Abstract][Full Text]
Hirsh, J., Bates, S. M.
(2001). Clinical Trials That Have Influenced the Treatment of Venous Thromboembolism: A Historical Perspective. ANN INTERN MED
134: 409-417
[Abstract][Full Text]
Breddin, H. K., Hach-Wunderle, V., Nakov, R., Kakkar, V. V., The CORTES Investigators,
(2001). Effects of a Low-Molecular-Weight Heparin on Thrombus Regression and Recurrent Thromboembolism in Patients with Deep-Vein Thrombosis. NEJM
344: 626-631
[Abstract][Full Text]
Merli, G., Spiro, T. E., Olsson, C.-G., Abildgaard, U., Davidson, B. L., Eldor, A., Elias, D., Grigg, A., Musset, D., Rodgers, G. M., Trowbridge, A. A., Yusen, R. D., Zawilska, K., for the Enoxaparin Clinical Trial Group*,
(2001). Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease. ANN INTERN MED
134: 191-202
[Abstract][Full Text]
Ginsberg, J. A., Crowther, M. A., White, R. H., Ortel, T. L.
(2001). Anticoagulation Therapy. ASH Education Book
2001: 339-357
[Abstract][Full Text]
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., Dalen, J. E.
(2001). Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest
119
: 64S-94S
[Full Text]
Levine, M. N., Raskob, G., Landefeld, S., Kearon, C.
(2001). Hemorrhagic Complications of Anticoagulant Treatment. Chest
119
: 108S-121S
[Full Text]
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., Weg, J. G.
(2001). Antithrombotic Therapy for Venous Thromboembolic Disease. Chest
119
: 176S-193S
[Full Text]
Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., Ginsberg, J. S.
(2000). Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy. Arch Intern Med
160: 3431-3436
[Abstract][Full Text]
Collen, A., Smorenburg, S. M., Peters, E., Lupu, F., Koolwijk, P., Van Noorden, C., van Hinsbergh, V. W. M.
(2000). Unfractionated and Low Molecular Weight Heparin Affect Fibrin Structure and Angiogenesis in Vitro. Cancer Res.
60: 6196-6200
[Abstract][Full Text]
O'Shaughnessy, D., Miles, J., Wimperis, J.
(2000). UK patients with deep-vein thrombosis can be safely treated as out-patients. QJM
93: 663-667
[Abstract][Full Text]
Bauer, K. A.
(2000). Venous Thromboembolism in Malignancy. JCO
18: 3065-3067
[Full Text]
Hutten, B. A., Prins, M. H., Gent, M., Ginsberg, J., Tijssen, J. G. P., Buller, H. R.
(2000). Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis. JCO
18: 3078-3083
[Abstract][Full Text]
Zidane, M., Schram, M. T., Planken, E. W., Molendijk, W. H., Rosendaal, F. R., van der Meer, F. J. M., Huisman, M. V.
(2000). Frequency of Major Hemorrhage in Patients Treated With Unfractionated Intravenous Heparin for Deep Venous Thrombosis or Pulmonary Embolism: A Study in Routine Clinical Practice. Arch Intern Med
160: 2369-2373
[Abstract][Full Text]
(2000). Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J
21: 1301-1336
Streiff, M. B.
(2000). Vena caval filters: a comprehensive review. Blood
95: 3669-3677
[Abstract][Full Text]
Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O'Fallon, W. M., Melton III, L. J.
(2000). Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Cohort Study. Arch Intern Med
160: 761-768
[Abstract][Full Text]
Meignan, M., Rosso, J., Gauthier, H., Brunengo, F., Claudel, S., Sagnard, L., d'Azemar, P., Simonneau, G., Charbonnier, B.
(2000). Systematic Lung Scans Reveal a High Frequency of Silent Pulmonary Embolism in Patients With Proximal Deep Venous Thrombosis. Arch Intern Med
160: 159-164
[Abstract][Full Text]
Dolovich, L. R., Ginsberg, J. S., Douketis, J. D., Holbrook, A. M., Cheah, G.
(2000). A Meta-analysis Comparing Low-Molecular-Weight Heparins With Unfractionated Heparin in the Treatment of Venous Thromboembolism: Examining Some Unanswered Questions Regarding Location of Treatment, Product Type, and Dosing Frequency. Arch Intern Med
160: 181-188
[Abstract][Full Text]
Wakefield, T. W.
(2000). The Safety, Efficacy, and Cost Efficiency of Outpatient Treatment of Acute Deep Venous Thrombosis with Low Molecular Weight Heparin. PERSPECT VASC SURG ENDOVASC THER
13: 19-25
[Abstract]
Carman, T. L., Fernandez, B. B., Yusen, R. D., Haraden, B. M., Gage, B. F., Rubin, B. G., Botney, M. D.
(1999). Outpatient Treatment of Deep Venous Thrombosis. Chest
116: 1492-1493
[Full Text]
Anand, S. S., Bates, S., Ginsberg, J. S., Levine, M., Buller, H., Prins, M., Haley, S., Kearon, C., Hirsh, J., Gent, M.
(1999). Recurrent Venous Thrombosis and Heparin Therapy: An Evaluation of the Importance of Early Activated Partial Thromboplastin Times. Arch Intern Med
159: 2029-2032
[Abstract][Full Text]
Zed, P. J., Tisdale, J. E., Borzak, S.
(1999). Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes. Arch Intern Med
159: 1849-1857
[Abstract][Full Text]
Spyropoulos, A. C., Harrison, L., Liebowitz, R. S.
(1999). Outpatient Protocols for Treatment of Venous Thromboembolism Using Low-Molecular-Weight Heparin: To Treat or Not to Treat at Home. Arch Intern Med
159: 1139-1140
[Full Text]
Aguilar, D., Goldhaber, S. Z.
(1999). Clinical Uses of Low-Molecular-Weight Heparins. Chest
115: 1418-1423
[Full Text]
Yusen, R. D., Haraden, B. M., Gage, B. F., Woodward, R. S., Rubin, B. G., Botney, M. D.
(1999). Criteria for Outpatient Management of Proximal Lower Extremity Deep Venous Thrombosis. Chest
115: 972-979
[Abstract][Full Text]
Fraser, J. D., Anderson, D. R.
(1999). Deep Venous Thrombosis: Recent Advances and Optimal Investigation with US. Radiology
211: 9-24
[Full Text]
Kuijer, P. M. M., Hutten, B. A., Prins, M. H., Buller, H. R.
(1999). Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous Thromboembolism. Arch Intern Med
159: 457-460
[Abstract][Full Text]
